EUROPROTEOME announces collaboration with Altana Pharma in molecular profiling of clinical cancer repositories
EUROPROTEOME AG announced that it has entered into a collaboration for evaluation of approaches for molecular profiling of tissue specimens from cancer patients with ALTANA Pharma AG.
Under the agreement, EUROPROTEOME will use its proprietary collection of purified human cancer cells to analyze molecular expression of a panel of cancer targets. The molecular data will then be aligned with a selected set of clinical data such as cancer stage and disease progression in order to assess disease associated expression signatures and prioritize molecular target candidates for therapeutic intervention with novel drugs and accompanying diagnostics for disease control. Financial terms were not disclosed.
"We believe this collaboration will greatly enhance our knowledge about the clinical relevance of novel cancer targets," said Dr. Karl Sanders, Head Therapeutic Area Oncology at ALTANA Pharma AG. "Molecular profiling of tissue specimens from cancer patients will be an important step in the development of novel cancer drugs. This will allow for the stratification of patients who will benefit most from targeted cancer therapeutics. EUROPROTEOME is an ideal partner to achieve this objective."
Christian Knobloch, M.D., Vice President Business Development, EUROPROTEOME, added: "We are very pleased that the value of EEUROPROTEOME's capabilities to merge both molecular and clinical data is being recognized by a top tier pharmaceutical company. We look forward to a successful collaboration."
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.